Abcam

OverviewSuggest Edit

Abcam is a life sciences company that identifies and develops biological reagents and tools. The company provides antibodies, binders, and assays, including primary and secondary antibodies, ELISA and matched antibody pairs, knockout cell lines and lysates, multiplex assays, agonists, antagonists, activators, inhibitors, as well as proteins and peptides. Its products are applicable in research, drug discovery, and diagnostics.

TypePublic
Founded1998
Websiteabcam.com
Employee Ratings4.5More
View Jobs (126)

Recent NewsAll News

Latest Updates

Employees (est.) (Jun 2020)1,492(+30%)
Job Openings126
Revenue (FY, 2020)£260 M
Share Price (Jul 2021)$17.5
Cybersecurity ratingBMore

Key People/Management at Abcam

Alan Hirzel

Alan Hirzel

Chief Executive Officer
Peter Allen

Peter Allen

Non-Executive Chairman
Jonathan Milner

Jonathan Milner

Deputy Chairman
Subham Basu

Subham Basu

Director of Strategy, Immuno-Oncology, Cambridge, UK
Michael S Baldock

Michael S Baldock

Chief Financial Officer
Giles Kerr

Giles Kerr

Non-Executive Director
Show more

Abcam Office Locations

Abcam has offices in Branford, Burlingame, Cambridge, Eugene and in 4 other locations
Hangzhou Shi, CN
1418-32 Moganshan Rd, Gongshu Qu
Shanghai, CN
Unit 5401, Bldg. 5, No. 338 Galileo Rd. Pudong
Hong Kong, HK
Lakeside 1, 8 Science and Technology Ave W, Science Park
Tokyo, JP
2-2-1 Nihonbashi Horidome-cho
Branford, CT, US
688 E Main St
Burlingame, CA, US
863 Mitten Rd
Show all (8)

Abcam Financials and Metrics

Abcam Revenue

Embed Graph
View revenue for all periods
Abcam's revenue was reported to be £260 m in FY, 2020
GBP

Revenue (FY, 2020)

260.0m

Revenue growth (FY, 2019 - FY, 2020), %

0%

Gross profit (FY, 2020)

180.2m

Gross profit margin (FY, 2020), %

69.3%

Net income (FY, 2020)

12.5m

EBIT (FY, 2020)

10.5m

Market capitalization (21-Jul-2021)

4.0b

Closing stock price (21-Jul-2021)

17.5

Cash (30-Jun-2020)

187.3m

EV

4.0b
Abcam's current market capitalization is $4 b.
Annual
GBPFY, 2018FY, 2019FY, 2020

Revenue

233.2m259.9m260.0m

Revenue growth, %

11%0%

Cost of goods sold

70.2m76.7m79.8m

Gross profit

163.0m183.2m180.2m
Half Year
GBPH1, 2019H1, 2020

Revenue

124.7m138.2m

Cost of goods sold

37.1m41.9m

Gross profit

87.6m96.3m

Gross profit Margin, %

70%70%
show all
Annual
GBPFY, 2018FY, 2019FY, 2020

Cash

90.2m87.1m187.3m

Accounts Receivable

24.9m29.3m31.4m

Inventories

29.6m36.0m40.7m

Current Assets

159.9m171.8m278.8m
Half Year
GBPH1, 2019H1, 2020

Cash

83.2m189.9m

Inventories

32.1m39.5m

Current Assets

146.1m277.4m

PP&E

32.7m41.0m
show all
Annual
GBPFY, 2018FY, 2019FY, 2020

Net Income

62.2m45.0m12.5m

Depreciation and Amortization

12.9m15.4m29.9m

Inventories

(5.8m)(6.1m)(1.1m)

Accounts Payable

3.4m7.7m2.4m
Half Year
GBPH1, 2019H1, 2020

Net Income

27.7m26.1m

Depreciation and Amortization

6.9m6.4m

Inventories

(2.5m)(4.6m)

Accounts Payable

(1.3m)1.7m
show all
GBPFY, 2018

Revenue/Employee

221.3k

Financial Leverage

1.2 x

P/E Ratio

32.5
Show all financial metrics

Abcam Operating Metrics

FY, 2018FY, 2019FY, 2020

Countries

140140130

Locations

111115

Products

110 k122 k130 k
Show all operating metrics

Abcam Acquisitions / Subsidiaries

Company NameDateDeal Size
Abcam Trading (Shanghai) Co. Ltd.
Abcam US Group Holdings Inc.
Abcam (US) Ltd.
Epitomics Inc

Abcam Revenue Breakdown

Embed Graph

Abcam revenue breakdown by business segment: 93.5% from Catalogue and 6.5% from Custom Products and Licensing

Abcam revenue breakdown by geographic segment: 43.2% from The Americas, 26.7% from EMEA, 15.2% from China, 7.2% from Japan and 7.7% from Rest of Asia Pacific

Abcam Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

Learn more about our premium products
SecurityScorecard logo

Abcam Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Abcam Online and Social Media Presence

Abcam's Trends

Embed Graph

Abcam News and Updates

July 13, 2021

Abcam opens new US facility in Boston, MA

Supporting accelerated growth of R&D, manufacturing, and commercial activities with new 100,000 sq-ft state-of-the-art facility Reinforcing commitment to the region as Abcam approaches 20 years of US presence CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a...
June 01, 2021

Anti-nuclear Antibody (ANA) Testing Market: COVID-19 Focused Report|Featuring Abbott Laboratories and Abcam Plc among others|Technavio

NEW YORK, June 1, 2021 /PRNewswire/ -- The antinuclear antibody (ANA) testing market is expected to grow by USD 362.30 million during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the antinuclear antibody (ANA) testing...
April 12, 2021

Abcam and MEDx extend precision medicine strategic partnership

CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to develop…
March 24, 2021

Abcam Wins Industry Awards from CiteAb

CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘Significant Individual Impact’ and the Comp…
March 04, 2021

Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector

CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer ser…
February 26, 2021

Abcam to Report Interim Results on Monday, March 8, 2021

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST…
Show more

Abcam Blogs

June 23, 2021

Seven tech advances that help you discover more, faster

Once upon a time, there was a world without technology. Or was there? Technology may not have looked the same 200 years ago, but it has constantly been evolving. From the development of horse-drawn carriages to jet engines, humans have strived to create new devices to advance our understanding. When…
June 09, 2021

How to write a scientific paper quickly and easily?

Who wouldn’t like to see their scientific paper published in a good journal? Yet, putting together a manuscript for the first time might feel like a complex, challenging process. So here we break this task into simple, doable steps and share a few tips on making your writing process smooth and quick…
May 10, 2021

Practical tips to endure the PhD Marathon

[A note from the editor: Ananya is a PhD student in Marine Science at King Abdullah University of Science & Technology, Saudi Arabia. Her research focuses on the impacts of oil pollution in three critical marine environments: the Arabian Gulf, the Great Barrier Reef, and the Red Sea. She looks a…
February 26, 2021

With great power comes great responsibility: understanding the importance of mentoring

The origins of mentoring Mentoring. A word we often hear throughout our career, but what does it really mean? We can begin to answer this question by probing the origins of the word ‘mentor.’ I was amazed to discover that the term traces back to the 8th Century BC when Athena disguises herself as Od…
January 11, 2021

Lab new year resolutions

It’s that time of year again. Time to tell yourself you will do things. The things you keep meaning to do, but you don’t. January – the month of getting things in order. At least for a week or two. Then you go back to your old routine. Obviously, no one likes having to do […] The post Lab new year r…
December 04, 2020

Under the Microscope: PCR and COVID-19

What is PCR? Polymerase Chain Reactions (PCRs) are often used in research to amplify genetic material, and, as a scientist, you probably don’t give the process a second thought. However, the term PCR has now left the laboratory and worked its way into every household due to its use in the COVID-19 t…
Show more

 Abcam Frequently Asked Questions

  • When was Abcam founded?

    Abcam was founded in 1998.

  • Who are Abcam key executives?

    Abcam's key executives are Alan Hirzel, Peter Allen and Jonathan Milner.

  • How many employees does Abcam have?

    Abcam has 1,492 employees.

  • What is Abcam revenue?

    Latest Abcam annual revenue is £260 m.

  • What is Abcam revenue per employee?

    Latest Abcam revenue per employee is £174.3 k.

  • Who are Abcam competitors?

    Competitors of Abcam include BioLegend, Bio-Techne and Humanigen.

  • Where are Abcam offices?

    Abcam has offices in Branford, Burlingame, Cambridge, Eugene and in 4 other locations.

  • How many offices does Abcam have?

    Abcam has 8 offices.